rhTM suppresses inflammation mainly by binding to HMGB-1 and it also suppresses excess coagulation by forming a complex with thrombin and by activating protein C. Several recent clinical studies suggested the possibility that rhTM improve the prognosis of AE-IPF when it used in combination with corticosteroids. This evidence concerns the gene HMGB1 and idiopathic pulmonary fibrosis.